

Amendments to the Claims

Claims 1-8 (Cancelled).

Claim 9 (Currently Amended) ~~The method of Claim 3, A method for~~
inhibiting vascular smooth muscle cell proliferation after balloon injury of a blood
vessel in a mammal, comprising:

introducing a polynucleotide to said blood vessel by catheter instillation at
the site of said balloon injury after said balloon injury, said polynucleotide
comprising a thymidine kinase gene in a eukaryotic expression vector wherein said
~~expression vector containing said thymidine kinase gene is complexed with a~~
nonviral vector;

expressing said thymidine kinase gene to produce thymidine kinase protein
in smooth muscle cells of said blood vessel; and

then administering to said mammal an effective amount of a DNA
replication-inhibiting nucleoside analog capable of being phosphorylated by said
thymidine kinase protein, whereby said phosphorylated analog is preferentially
incorporated into the DNA of proliferating cells, and whereby said proliferating cells
are killed.

Claim 10 (Previously Presented) The method of Claim 9, wherein said nonviral vector is a liposome.

Claim 11 (Previously Presented) The method of Claim 9, wherein said nonviral vector is a receptor ligand and said expression vector-ligand complex binds to the receptor.

Claims 12-20 (Cancelled).

Claim 21 (New) The method of Claim 9, wherein said eukaryotic expression vector is a viral vector.

Claim 22 (New) The method of Claim 9, further comprising a polyoma virus enhancer upstream of said thymidine kinase gene.

Claim 23 (New) The method of any one of Claims 9, 10, 11, 21 or 22, wherein said nucleoside analog is ganciclovir or acyclovir.

Claim 24 (New) The method of Claim 23, wherein said phosphorylated analog is further phosphorylated by intracellular enzymes.
